More Recce Pharmaceuticals Ltd. news
Recce Pharmaceuticals Ltd.ASX: RCE

S&P DJI Announces March 2021 Quarterly Rebalance

Mar 12, 2021 at 6:23 AM EST · Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · Mar 12, 2021 at 6:23 AM EST · 9 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-march-2021-quarterly-rebalance-93

Recce Pharmaceuticals Ltd. on 6ix

Earlier from Recce Pharmaceuticals

  • Recce Pharmaceuticals Dual Lists on Frankfurt Stock ExchangeMar 7, 2021
  • Appendix 4D and Half Yearly ReportFeb 25, 2021
  • Recce Applies for Dual Listing on Frankfurt Stock ExchangeFeb 23, 2021
  • Fiona Stanley Hospital Phase I/II Clinical Trial AgreementFeb 15, 2021
  • Further Encouraging COVID Results at DohertyFeb 11, 2021

Later from Recce Pharmaceuticals

  • Anti-Viral Patent Granted in EU for RECCE Anti-InfectivesMar 30, 2021
  • Positive Sinusitis Data Against InfectionMar 31, 2021
  • Positive Sinusitis Patient Update - Special Access SchemeApr 7, 2021
  • RECCE 327 Registered for Topical Burns Study in HumansApr 15, 2021
  • Positive Data on RECCE 327 Against All Six ESKAPE PathogensMay 3, 2021
All Recce Pharmaceuticals news releases↗

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer